Pandion Therapeutics Competitors

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Pandion Therapeutics (NASDAQ:PAND) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk and analyst recommendations.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Arrowhead Pharmaceuticals and Pandion Therapeutics, as provided by MarketBeat.com.

Arrowhead Pharmaceuticals currently has a consensus target price of $85.3077, suggesting a potential upside of 26.27%. Pandion Therapeutics has a consensus target price of $44.25, suggesting a potential downside of 26.31%. Given Arrowhead Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Arrowhead Pharmaceuticals is more favorable than Pandion Therapeutics.

Profitability

This table compares Arrowhead Pharmaceuticals and Pandion Therapeutics' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Arrowhead Pharmaceuticals and Pandion Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Pandion Therapeutics has lower revenue, but higher earnings than Arrowhead Pharmaceuticals.

Institutional and Insider Ownership

65.5% of Arrowhead Pharmaceuticals shares are held by institutional investors. Comparatively, 35.7% of Pandion Therapeutics shares are held by institutional investors. 4.0% of Arrowhead Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Arrowhead Pharmaceuticals beats Pandion Therapeutics on 6 of the 11 factors compared between the two stocks.

GW Pharmaceuticals (NASDAQ:GWPH) and Pandion Therapeutics (NASDAQ:PAND) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk and analyst recommendations.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for GW Pharmaceuticals and Pandion Therapeutics, as provided by MarketBeat.com.

GW Pharmaceuticals currently has a consensus target price of $204.0909, suggesting a potential downside of 6.69%. Pandion Therapeutics has a consensus target price of $44.25, suggesting a potential downside of 26.31%. Given GW Pharmaceuticals' higher possible upside, research analysts clearly believe GW Pharmaceuticals is more favorable than Pandion Therapeutics.

Profitability

This table compares GW Pharmaceuticals and Pandion Therapeutics' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares GW Pharmaceuticals and Pandion Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

GW Pharmaceuticals has higher revenue and earnings than Pandion Therapeutics.

Institutional and Insider Ownership

81.0% of GW Pharmaceuticals shares are held by institutional investors. Comparatively, 35.7% of Pandion Therapeutics shares are held by institutional investors. 3.1% of GW Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

GW Pharmaceuticals beats Pandion Therapeutics on 6 of the 11 factors compared between the two stocks.

Pandion Therapeutics (NASDAQ:PAND) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.

Insider & Institutional Ownership

35.7% of Pandion Therapeutics shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations for Pandion Therapeutics and Ascendis Pharma A/S, as reported by MarketBeat.

Pandion Therapeutics currently has a consensus price target of $44.25, suggesting a potential downside of 26.31%. Ascendis Pharma A/S has a consensus price target of $187.6667, suggesting a potential upside of 52.69%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, analysts plainly believe Ascendis Pharma A/S is more favorable than Pandion Therapeutics.

Valuation and Earnings

This table compares Pandion Therapeutics and Ascendis Pharma A/S's gross revenue, earnings per share and valuation.

Pandion Therapeutics has higher earnings, but lower revenue than Ascendis Pharma A/S.

Profitability

This table compares Pandion Therapeutics and Ascendis Pharma A/S's net margins, return on equity and return on assets.

Summary

Pandion Therapeutics beats Ascendis Pharma A/S on 6 of the 11 factors compared between the two stocks.

Pandion Therapeutics (NASDAQ:PAND) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.

Insider & Institutional Ownership

35.7% of Pandion Therapeutics shares are owned by institutional investors. Comparatively, 65.7% of TG Therapeutics shares are owned by institutional investors. 13.2% of TG Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations for Pandion Therapeutics and TG Therapeutics, as reported by MarketBeat.

Pandion Therapeutics currently has a consensus price target of $44.25, suggesting a potential downside of 26.31%. TG Therapeutics has a consensus price target of $64.00, suggesting a potential upside of 39.37%. Given TG Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe TG Therapeutics is more favorable than Pandion Therapeutics.

Valuation and Earnings

This table compares Pandion Therapeutics and TG Therapeutics' gross revenue, earnings per share and valuation.

Pandion Therapeutics has higher revenue and earnings than TG Therapeutics.

Profitability

This table compares Pandion Therapeutics and TG Therapeutics' net margins, return on equity and return on assets.

Summary

TG Therapeutics beats Pandion Therapeutics on 6 of the 11 factors compared between the two stocks.

Pandion Therapeutics (NASDAQ:PAND) and Ionis Pharmaceuticals (NASDAQ:IONS) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.

Insider & Institutional Ownership

35.7% of Pandion Therapeutics shares are owned by institutional investors. Comparatively, 84.1% of Ionis Pharmaceuticals shares are owned by institutional investors. 2.4% of Ionis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations for Pandion Therapeutics and Ionis Pharmaceuticals, as reported by MarketBeat.

Pandion Therapeutics currently has a consensus price target of $44.25, suggesting a potential downside of 26.31%. Ionis Pharmaceuticals has a consensus price target of $57.9091, suggesting a potential upside of 41.14%. Given Ionis Pharmaceuticals' higher possible upside, analysts plainly believe Ionis Pharmaceuticals is more favorable than Pandion Therapeutics.

Valuation and Earnings

This table compares Pandion Therapeutics and Ionis Pharmaceuticals' gross revenue, earnings per share and valuation.

Ionis Pharmaceuticals has higher revenue and earnings than Pandion Therapeutics.

Profitability

This table compares Pandion Therapeutics and Ionis Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Ionis Pharmaceuticals beats Pandion Therapeutics on 9 of the 11 factors compared between the two stocks.

Pandion Therapeutics (NASDAQ:PAND) and Allakos (NASDAQ:ALLK) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.

Insider & Institutional Ownership

35.7% of Pandion Therapeutics shares are owned by institutional investors. Comparatively, 65.4% of Allakos shares are owned by institutional investors. 44.8% of Allakos shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations for Pandion Therapeutics and Allakos, as reported by MarketBeat.

Pandion Therapeutics currently has a consensus price target of $44.25, suggesting a potential downside of 26.31%. Allakos has a consensus price target of $181.50, suggesting a potential upside of 72.32%. Given Allakos' stronger consensus rating and higher possible upside, analysts plainly believe Allakos is more favorable than Pandion Therapeutics.

Valuation and Earnings

This table compares Pandion Therapeutics and Allakos' gross revenue, earnings per share and valuation.

Pandion Therapeutics has higher revenue and earnings than Allakos.

Profitability

This table compares Pandion Therapeutics and Allakos' net margins, return on equity and return on assets.

Summary

Allakos beats Pandion Therapeutics on 5 of the 9 factors compared between the two stocks.